StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2021, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 22 Nov 2019 20:41:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form F-6EF Mitsubishi Tanabe Pharma Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html Fri, 22 Nov 2019 20:41:00 -0400 4508 M3C MTZXF Form F-6EF Mitsubishi Tanabe Pharma Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html Fri, 22 Nov 2019 20:41:00 -0400 4508 M3C MTZXF Form F-6EF Mitsubishi Tanabe Pharma Filed by: JPMorgan Chase Bank, N.A. - ADR Depositary http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++F-6EF++++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+JPMorgan+Chase+Bank%2C+N.A.+-+ADR+Depositary/16172484.html Fri, 22 Nov 2019 20:41:00 -0400 4508 M3C MTZXF Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html for the full story. http://www.streetinsider.com/Press+Releases/Salix+Enters+Into+Exclusive+License+Agreement+With+Mitsubishi+Tanabe+Pharma+To+Develop+And+Commercialize+Late+Stage+Investigational+S1P+Modulator+For+The+Treatment+Of+Inflammatory+Bowel+Disease/15404974.html Thu, 25 Apr 2019 07:00:00 -0400 4188 4508 BHC BHC M3C MTLHY MTZPY Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html for the full story. http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html Wed, 18 Oct 2017 04:23:00 -0400 4508 A.05910142 NDRM Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html for the full story. http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html Wed, 18 Oct 2017 04:23:00 -0400 4508 A.05910142 NDRM Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html for the full story. http://www.streetinsider.com/Press+Releases/Mitsubishi+Tanabe+Pharma+Corporation+Completes+Acquisition+of+NeuroDerm/13398660.html Wed, 18 Oct 2017 04:23:00 -0400 4508 A.05910142 NDRM Form F-6 POS Mitsubishi Tanabe Pharma Filed by: Deutsche Bank Trust Co Americas/ ADR Group http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html Fri, 29 Sep 2017 13:28:00 -0400 4508 M3C MTZXF Form F-6 POS Mitsubishi Tanabe Pharma Filed by: Deutsche Bank Trust Co Americas/ ADR Group http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html Fri, 29 Sep 2017 13:28:00 -0400 4508 M3C MTZXF Form F-6 POS Mitsubishi Tanabe Pharma Filed by: Deutsche Bank Trust Co Americas/ ADR Group http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++F-6+POS++++Mitsubishi+Tanabe+Pharma+++++++++++++++Filed+by%3A+Deutsche+Bank+Trust+Co+Americas+ADR+Group/13344214.html Fri, 29 Sep 2017 13:28:00 -0400 4508 M3C MTZXF NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html for the full story. http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Mon, 24 Jul 2017 02:00:00 -0400 4508 A.05786303 A.31825268 NDRM NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html for the full story. http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Mon, 24 Jul 2017 02:00:00 -0400 4508 A.05786303 A.31825268 NDRM NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html for the full story. http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Mon, 24 Jul 2017 02:00:00 -0400 4508 A.05786303 A.31825268 NDRM NeuroDerm Enters Definitive Agreement to be Acquired by Mitsubishi Tanabe Pharma Corporation for US$1.1 Billion in Cash http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html for the full story. http://www.streetinsider.com/Press+Releases/NeuroDerm+Enters+Definitive+Agreement+to+be+Acquired+by+Mitsubishi+Tanabe+Pharma+Corporation+for+US%241.1+Billion+in+Cash/13120576.html Mon, 24 Jul 2017 02:00:00 -0400 4508 A.05786303 A.31825268 NDRM TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html for the full story. http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Tue, 01 Nov 2016 11:01:00 -0400 102940 4188 4508 A.06822034 M3C MTLHY MTZPY TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html for the full story. http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Tue, 01 Nov 2016 11:01:00 -0400 102940 4188 4508 A.06822034 M3C MTLHY MTZPY TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html for the full story. http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Tue, 01 Nov 2016 11:01:00 -0400 102940 4188 4508 A.06822034 M3C MTLHY MTZPY TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html for the full story. http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Tue, 01 Nov 2016 11:01:00 -0400 102940 4188 4508 A.06822034 M3C MTLHY MTZPY TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa™, the World's First Cell-Mediated Gene Therapy for Degenerative Osteoarthritis http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html for the full story. http://www.streetinsider.com/Press+Releases/TissueGene+Licensee%2C+Kolon+Life+Science%2C+Partners+with+Mitsubishi+Tanabe+Pharma+to+Develop+and+Commercialize+Invossa%E2%84%A2%2C+the+World%27s+First+Cell-Mediated+Gene+Therapy+for+Degenerative+Osteoarthritis/12191247.html Tue, 01 Nov 2016 11:01:00 -0400 102940 4188 4508 A.06822034 M3C MTLHY MTZPY